Dec 2019 $60 M No. 8 $50 to $250 million 5
Kinex Pharmaceuticals LLC: Raise no. 8, Dec 2019 × Investors in this round 5 investors had bought by the notice of Dec 11, 2019: 5 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $60 M of $60 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $1,000,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Jeffrey Yordon · Executive Officer Johnson Lau · Executive Officer, Director Randoll Sze · Executive Officer Rudolf Kwan · Executive Officer Simon Pedder · Executive Officer William Zuo · Executive Officer Benson Tsang · Director Jinn Wu · Director John Koh · Director John Vierling · Director Jordan Kanfer · Director Kim Campbell · Director Manson Fok · Director Stephanie Davis · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round SunTrust Robinson Humphrey, Inc. (CRD 6271) · Atlanta, Georgia Sold in CT, NY Signed by Teresa Bair, Corporate Secretary. Source: SEC Form D, newest notice filed Dec 11, 2019. Read the notice at the SEC .
equity SEC May 2019 $100 M No. 7 $50 to $250 million 4
Kinex Pharmaceuticals LLC: Raise no. 7, May 2019 × Investors in this round 4 investors had bought by the notice of May 15, 2019: 4 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $100 M of $100 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue $25 million to $100 million
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Jeffrey Yordon · Executive Officer Johnson Lau · Executive Officer, Director Randoll Sze · Executive Officer Rudolf Kwan · Executive Officer Simon Pedder · Executive Officer William Zuo · Executive Officer Benson Tsang · Director Jinn Wu · Director John Koh · Director John Vierling · Director Jordan Kanfer · Director Kim Campbell · Director Manson Fok · Director Stephanie Davis · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Teresa Bair, Corporate Secretary. Source: SEC Form D, newest notice filed May 15, 2019. Read the notice at the SEC .
equity SEC Jun 2018 $50 M No. 6 $50 to $250 million 1
Kinex Pharmaceuticals LLC: Raise no. 6, Jun 2018 × Investors in this round 1 investor had bought by the notice of Jul 17, 2018: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $50 M of $50 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Jeffrey Kwan Hung Yordon · Executive Officer Johnson Lau · Executive Officer Li Kwan Hung Shen · Executive Officer Rudolf Kwan Hung Kwan · Executive Officer Simon Kwan Hung Pedder · Executive Officer William Kwan Hung Zuo · Executive Officer Benson Kwan Hung Tsang · Director Jinn Wu · Director Kim Campbell · Director Manson Fok · Director Sheldon Trainor-Degirolamo · Director SongYi Zhang · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the use of proceeds: “Some of the proceeds may be used for general working capital purposes which may include the payment of salaries and other fees to those listed in item 3.”Signed by Johnson Lau, Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 17, 2018. Read the notice at the SEC .
equity, options SEC Apr 2015 $48 M No. 5 $10 to $50 million 9
Kinex Pharmaceuticals LLC: Raise no. 5, Apr 2015 × Investors in this round 9 investors had bought by the notice of May 20, 2015: 9 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $48 M of $63 M offered; $15 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Flint Besecker · Executive Officer, Director Johnson Lau · Executive Officer, Director Charles Lannon · Director Jinn Wu · Director Michael Murphy · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Flint Besecker, Chief Operating Officer and Executive Vice President. Source: SEC Form D, newest notice filed May 20, 2015. Read the notice at the SEC .
equity SEC Apr 2015 $10 M Issued in a merger or acquisition $10 to $50 million 2
Kinex Pharmaceuticals LLC: Private sale, Apr 2015 × Investors in this round 2 investors had bought by the notice of Jun 16, 2015: 2 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $10 M of $10 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Flint Besecker · Executive Officer, Director Johnson Lau · Executive Officer, Director Jinn Wu · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On a merger: “Stock was issued in connection with an acquisition by the Company.”Signed by Flint Besecker, Board Director and Chief Operating Officer. Source: SEC Form D, newest notice filed Jun 16, 2015. Read the notice at the SEC .
equity SEC Mar 2015 $74 M No. 4 $50 to $250 million 9
Kinex Pharmaceuticals LLC: Raise no. 4, Mar 2015 × Investors in this round 9 investors had bought by the notice of Jun 16, 2015: 9 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $74 M (amount offered: indefinite)
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Flint Besecker · Executive Officer, Director Johnson Lau · Executive Officer, Director Jinn Wu · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Flint Besecker, Board Director and Chief Operating Officer. Source: SEC Form D, newest notice filed Jun 16, 2015. Read the notice at the SEC .
equity SEC Jul 2012 $5 M No. 3 $2 to $10 million 1
Kinex Pharmaceuticals LLC: Raise no. 3, Jul 2012 × Investors in this round 1 investor had bought by the notice of Aug 6, 2012: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $5 M of $40 M offered; $35 M still to sell
Smallest investment taken $25,000
What was sold equity
Meant to last a year or less
Issuer's revenue $1 million to $5 million
Sales commissions none
Finders' fees none
Paid to its own people $500,000 (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Limited Liability Company, incorporated in Delaware People named in the notice David Hangauer · Executive Officer Johnson Lau · Executive Officer, Director Lyn Dyster · Executive Officer Charles Lannon · Director Flint Besecker · Director Jean-Pierre Sommadossi · Director Jinn Wu · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the use of proceeds: “Executive Officer salaries”Signed by Lyn Dyster, Vice President. Source: SEC Form D, newest notice filed Aug 6, 2012. Read the notice at the SEC .
equity SEC Apr 2011 $5 M No. 2 $2 to $10 million 2
Kinex Pharmaceuticals LLC: Raise no. 2, Apr 2011 × Investors in this round 2 investors had bought by the notice of Apr 25, 2011: 2 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $5 M of $5 M offered; $0 M still to sell
Smallest investment taken $250,000
What was sold equity
Meant to last a year or less
Issuer's revenue $1 million to $5 million
Sales commissions none
Finders' fees none
Paid to its own people $150,000 (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Limited Liability Company, incorporated in Delaware People named in the notice Allen Barnett · Executive Officer, Director David Hangauer · Executive Officer Johnson Lau · Executive Officer, Director Lyn Dyster · Executive Officer Charles Lannon · Director David Hsia · Director Jinn Wu · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the use of proceeds: “Executive Officer salaries”Signed by Allen Barnett, Ceo. Source: SEC Form D, newest notice filed Apr 25, 2011. Read the notice at the SEC .
equity SEC Dec 2009 $4 M No. 1 $2 to $10 million 24
Kinex Pharmaceuticals LLC: Raise no. 1, Dec 2009 × Investors in this round 24 investors had bought by the notice of Feb 3, 2010: 24 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $4 M of $6 M offered; $2 M still to sell
Smallest investment taken $25,000
What was sold equity
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people $150,000 (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Limited Liability Company, incorporated in Delaware People named in the notice Allen Barnett · Executive Officer, Director David Hangauer · Executive Officer Johnson Lau · Executive Officer, Director Lyn Dyster · Executive Officer Charles Lannon · Director David Hsia · Director Jinn Wu · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the use of proceeds: “Executive Officer salaries”Signed by Allen Barnett, Ceo. Source: SEC Form D and 1 amendment, newest notice filed Feb 3, 2010. Read the notice at the SEC .
equity SEC